Proactive Investors - Run By Investors For Investors

Buds & Duds: Cannabis stocks take a breather; OrganiGram shares soar as it announces uplisting

Also on the move were The Supreme Cannabis Company, cbdMD, Namaste, TILT and Golden Leaf
cannabis in sun
OrganiGram shares jumped after it announced it was uplisting to the Nasdaq Global Select Market

Cannabis stocks rolled into Friday generally flat, after a busy week of key earnings reports and a host of acquisition news. 

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was up 0.1% to 277.9 points by Friday midday. The Horizons Marijuana Life Sciences Index ETF inched up 0.2% at C$20.37.


OrganiGram Holdings Inc (CVE:OGI) (OTCMKTS:OGRMF) shares jumped on Friday, as it announced it was uplisting to the Nasdaq Global Select Market, increasing its visibility to larger investors.

Shares were up 4.6% at C$10.86 in Canadian trading and up 4% at US$8.07 in New York. 

The Moncton, New Brunswick-company will list under the symbol OGI on May 21 and its common shares will continue to list and trade on the Canadian Venture Exchange, under the same symbol. 

READ: Canadian cannabis workers wouldn’t be denied entry into the US under new House bill

The Supreme Cannabis Company Inc (TSE:FIRE) (OTCMKTS:SPRWF) shares were also on the rise Friday, a day after it announced plans to acquire Langley, BC-based producer BlissCo Cannabis Corp (CSE:BLIS) in an all-stock deal it valued at C$48 million.

Shares of Supreme were up 1.4% at US$1.41, up 1.4% at C$1.89 in Toronto. 

Blissco has a 18,000 sq/ft production facility and produces cannabis oils. It received its production license in August 2018.

“Supreme Cannabis is the best positioned company in the cannabis space to help Blissco achieve its ambition of delivering innovative, quality assured full-spectrum cannabis products to the world,” said Damian Kettlewell, CEO of Blissco.

READ: cbdMD beats Street expectations in 2Q, with revenue boosts and strong sales growth

Also on the rise Friday was cbdMD Inc (NYSEAMERICAN:YCBD), which posted fiscal second-quarter revenues that came in ahead of expectation on Thursday.

The US cannabis company saw revenue jump 84% to $5.7 million, topping Street expectations of $3.2 million. Working capital increased to $12.3 million from $10.8 million in the prior quarter.

“Our goal is to build cbdMD into the most recognized CBD brand in the America,” Martin A. Sumichrast said. “Our strong second quarter results place us in a great position to accomplish this goal. Our e-commerce sales platform remains strong and has accounted for over 70% of our total net sales. On a store count basis, we have grown from under 600 doors in December 2018 to over 2,000 currently, and we continue to build momentum.”

Other gainers on Friday included Namaste Technologies Inc (CVE:N) (OTCMKTS:NXTTF), the cannabis e-commerce group, up 1.4% at C$0.72 in Toronto. 

The company hasn't released any news, however, it is currently undergoing an audit of its 2018 financial statements. 


TILT Holdings Inc (CSE:TILT) (OTCMKTS:SVVTF) shares continued to drop Friday, down 5.3% at C$1.80 in Toronto, down 7% at US$1.33 in New York.

The firm announced it was appointing a new interim CEO, Mark Scatterday, last week after it after reported a steep writedown in assets. Scatterday was the founder and CEO of Jupiter Research, a vaporization and inhalation device company, now a wholly-owned subsidiary of TILT.

Other laggards on Friday included Golden Leaf Holdings Ltd (CSE:GLH) (OTCMKTS:GLDFF), which was down 4.5% at C$0.10 in Toronto, but up 4% at US$0.08 in New York. 

Last week the firm announced it was appointing CFO Karyn Barsa as CEO and president of Golden Leaf. Barsa has served as CEO at Coyuchi, CEO at Investors’ Circle, CEO at Smith & Hawken, and COO and CFO at Patagonia.

Contact Katie Lewis at [email protected]

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full OGI profile View Profile

OrganiGram Holdings Timeline

Related Articles

cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
October 18 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use